London, 31 January 2009 Doc. Ref. EMEA/85080/2009

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Monthly Report of Application Procedures, Guidelines and Related Documents

The CVMP Monthly Report includes statistical data for the current and previous two years on Scientific Advice, Initial Evaluations, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures. In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

Applications for Medicinal Products for Veterinary Use and Maximum Residue Limits (MRLs)

Scientific Advice Requests						
	95-06	2007	2008	2009	Total	
Submitted	51	7	5	0	63	

Initial Evaluation					
	95- 06	2007	2008	2009	Total
Full ¹	83	14	13	1	111
Abridged/Generics	6	1	3	0	10
Withdrawals	11	0	1	0	12
Positive Opinions	69	9	13	0	91
Negative Opinions	1	0	0	0	1

Marketing Authorisations						
	95- 06	2007	2008	2009	Total	
Granted	66	9	13	1	89	
Withdrawals	1	0	1	0	2	
Not renewed	1	1	0	0	2	

Extensions - Annex II Applications ²						
	95- 06	2007	2008	2009	Total	
Submitted	47	9	4	0	60	
Withdrawals	1	0	0	0	1	
Positive Opinions	32	1	7	0	40	
Negative Opinions	0	0	0	0	0	

Variations – Applications submitted							
	95-06	2007	2008	2009	Total		
Type IA	238	29	23	3	342		
Type IB	236	24	25	0	342		
Type II	111	47	52	5	215		
Transfers	7	2	2	0	11		

¹ Initial applications submitted and validated: 121 applications in total (full + abridged), comprising 62 immunologicals and 59 pharmaceuticals. Negative opinions: in case of appeals, the opinion will not be counted twice.

² Extensions applications submitted and validated: 58 line extensions in total, comprising 11 immunologicals and 47 pharmaceuticals; one opinion can cover a number of extensions

Renewals					
	95-06	2007	2008	2009	Total
Submitted	29	14	7	1	51
Positive Opinions	29	11	8	1	49
Negative Opinions	0	0	0	0	0

Arbitration	Arbitrations and Community Referrals							
	95-06	2007	2008	2009	Total			
Referrals Submitted	21	6	11	1	39			
Opinions Reached	4	10	6	2	22			

Establishment of MRLs for new substances						
	95-06	2007	2008	2009	Total	
Submitted	63	2	1	0	66	
Withdrawals	5	0	0	0	5	
Positive Opinions ³	49	3	2	1	55	
Negative Opinions ⁴	6	0	1	0	7	

Extensions / Modifications/Extrapolations of MRLs							
	95- 06	2007	2008	2009	Total		
Submitted	95	1	2	1	99		
Withdrawals	4	0	0	0	4		
Positive Opinions ³	107	4	2	0	113		
Negative Opinions ⁴	6	0	0	0	6		
Extrapolations	45	0	5	0	50		

³ Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits ⁴ Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

CVMP Opinions in 2009 on Medicinal Products for Veterinary Use

Positive Opinions

Product Brand name INN	Marketing authorisation holder	Therapeutic area Target species Summary of indication	EMEA/CVMP Validation Opinion Active time Clock stop	European Commission Opinion received Date of decision Notification Official Journal

Negative Opinions

Pr	oduct	Marketing	Therapeutic area	EMEA/CVMP	European
-	Brand name	authorisation	 Target species 	 Validation 	Commission
•	INN	holder	 Summary of indication 	OpinionActive timeClock stop	Opinion receivedDate of decisionNotificationOfficial Journal

Withdrawals prior to opinion

Product Brand name INN	Marketing authorisation holder	Therapeutic area Target species Summary of indication	EMEA/CVMP Validation Opinion Active time Clock stop	European Commission Opinion received Date of decision Notification Official Journal

CVMP Opinions in 2009 on establishment of MRLs for new substances

Positive Opinions

Substance INN	Therapeutic area Target species	EMEA/CVMP Validation Opinion Active time Clock stop	 European Commission Opinion received Date of regulation Official Journal

Negative Opinions (Recommendation for inclusion in Annex IV or inability to recommend inclusion in any of the Annexes to Regulation 2377/90)

in any or and ramiones to regulation 20 / 11/0)			
Substance INN	Therapeutic area	EMEA/CVMP	European Commission
	 Target species 	 Validation 	 Opinion received
		Opinion	 Date of regulation
		 Active time 	 Official Journal
		 Clock stop 	

Arbitrations and Community Referrals in 2009

Type of referral	Date of clock start / CVMP opinion	Product nameINN
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	13/05/2008 15/01/2009	ENRO-K 10% oral solutionEnrofloxacin
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	13/05/2008 15/01/2009	 Unisol (avifox) 10% oral solution Enrofloxacin
Referral for arbitration – Art. 33(4) of Directive 2001/82/EC	15/01/2009 (clock start re-examination)	 Pharmasin 100% w/w water soluble granules Tylosine tartrate

Urgent procedures

Type of procedure	CVMP opinion	Product name

Guidelines and Working Documents in 2009

CVMP Efficacy

Reference number	Document title	Status

CVMP Environmental Risk Assessment (ERA)

Reference number	Document title	Status

CVMP Immunologicals

Reference number	Document title	Status

CVMP Pharmacovigilance

Reference number	Document title	Status
SOP-EMEA/599270/2007	SOP on Handling of pharmacovigilance Rapid Alerts (RAs) and Non Urgent Informaion (NUI)for veterinary use	Endorsed, January 2009

Joint CHMP/CVMP Quality

Reference number	Document title	Status
EMEA/CVMP/QWP/544461/2007	Guideline on the quality aspects of single-dose veterinary spot-on products	Adopted, January 2009
EMEA/CHMP/CVMP/QWP/66309 3/2008	Question and Answer document on Plastic Immediate Packaging Materials	Adopted, January 2009

CVMP Safety

Reference number	Document title	Status

CVMP Scientific Advisory Group on Antimicrobials

Reference number	Document title	Status

CVMP General

Reference number	Document title	Status
EMEA/INS/GCP/390778/2008	Procedure for the preparation of a risk- based programme for routine PhV Inspections of MAHs connected with Veterinary Centrally Authorised Products (CAPs)	Adopted, January 2009
EMEA/INS/GCP/85059/2008	Procedure for coordination of pharmacovigilance inspections requests by the CVMP	Adopted, January 2009